Home

Halozyme Therapeutics, Inc. - Common Stock (HALO)

59.66
-2.27 (-3.66%)
NASDAQ · Last Trade: Apr 5th, 12:24 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. (“Halozyme”) (NASDAQ: HALO) on behalf of the company’s shareholders.
By Kaskela Law LLC · Via Business Wire · September 17, 2024
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.
By ViiV Healthcare · Via Business Wire · June 22, 2021